Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the…

By R. Herrmann, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schüller, P. Saletti, J. Bauer, A. Figer, B. Pestalozzi and 10 more. Journal of Clinical Oncology, 2007

607 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/109c0fd6dc1e79badf768eae12fd1ee576d9141d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

Citations in the corpus

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, result): “Similarly, results from another smaller phase III trial evaluating this combination did not demonstrate an OS advantage for overall study population receiving the combination of gemcitabine with capecitabine, although a posthoc analysis showed OS to be significantly increased in the subgroup of pati”
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). (2010, background): “Negative phase III results despite promising single-arm phase II data are, unfortunately, a common outcome in pancreatic cancer trials.(3-10) These collective data suggest that in this disease, a single-arm, phase II trial design may not be not optimal.”
Stromal biology and therapy in pancreatic cancer (2010, positive): “For the combination capecitabine and gemcitabine versus gemcitabine alone, initial data suggest no significant advantage for overall survival.(83) Notably, a recent phase III trial revealed a trend towards improved overall survival, and a meta-analysis involving 935 patients showed a significant sur”